Navigation Links
Study analyzed SYMBICORT in children with persistent asthma
Date:5/20/2008

Wilmington, DE May 20, 2008 A new 12-week study2examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dehydrate) Inhalation Aerosol,2 in treating mild to moderate persistent asthma in children ages 6 to 15 years old2 who were previously treated with an inhaled corticosteroid (ICS).2 Of note, the study included efficacy assessments of nighttime symptoms, nighttime rescue medication use and rescue medication-free days in patients taking SYMBICORT compared to those taking formoterol dry powder inhaler (DPI) or budesonide pressurized metered-dose inhaler (pMDI). Results were presented today at the International Conference of the American Thoracic Society held in Toronto, Canada, May 16-21, 2008.

Children with asthma, who are not adequately controlled by ICS therapy, may have their sleep affected by asthma symptoms,6 said Kathy Lampl, MD, Director, Clinical Research, AstraZeneca. Combination therapy with inhaled ICS and LABA is one of the recommended regimens for children who have moderate to severe persistent asthma or are not controlled with ICS therapy alone, according to the NIH Guidelines. 7

AstraZeneca (NYSE:AZN) anticipates filing a supplemental new drug application with the Food and Drug Administration for the pediatric indication of SYMBICORT in the first half of 2008.

About the Study (Abstracts #K66 and K67)

The safety profile and efficacy measures of SYMBICORT were assessed during a 12-week randomized, double-blind, active-controlled study that evaluated 411 children ages 6 to 15 years old with mild to moderate persistent asthma1,2 previously treated with ICS therapy.1,2 After a two-week period during which patients discontinued their current asthma medications and received two inhalations twice-daily of budesonide pMDI 40 micrograms (mcg), 128 patients1,2 were randomized to receive treatment with SYMBICORT pMDI 40/4.5 mcg two inhalations
'/>"/>

Contact: Katie Neff
katie.neff@astrazeneca.com
302-885-9960
Edelman Public Relations
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... released a new blog post explaining the importance of keeping a ... of an auto insurance policy . , Clients who driver ... their vehicle insurance policies. The safety a vehicle offers from its ... of this, drivers should always carry a first aid kit in ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... - Adjusted Diluted EPS (1) was $0.42 -- Annual Guidance Narrowed to $2.05 to $2.18 Adjusted Diluted ... West Pharmaceutical Services, Inc. (NYSE: WST ) today announced its results for the first quarter ... Three Months Ended, ... ...
... April 30 Quigley Pharma Inc., www.quigleyco.com ... Corporation (Nasdaq: QGLY ) announced today that ... of diabetic peripheral neuropathy, demonstrated a significant improvement in ... the group treated with QR333. The compound was ...
... PARK CITY, Utah, April 30 Nutraceutical International Corporation (Nasdaq: ... 2009 second quarter ended March 31, 2009. Net sales ... to $44.4 million for the same quarter of fiscal 2008.Primarily ... recession and the related turmoil in the equity markets, there ...
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), ... the following 2009 first quarter results: , ... revenues of $288.9 million for the quarter ended March 29, ... $77.8 million from its CareCentrix business unit, for the quarter ...
... April 3 In conjunction with its first quarter 2009 earnings ... 2009), Covance Inc. (NYSE: CVD ) is pleased to ... will be broadcast live over the Internet on Thursday, April 30, ... First Quarter 2009 Earnings Webcast and Slide Presentation, ...
... increases 9 percent to $24.9 billion- GAAP earnings from ... decrease 10 percent to $350 million on a non-GAAP ... decline 15 percent to $0.87 and decrease 10 percent ... Cardinal Health, a global provider of products and ...
Cached Medicine News:Health News:West Announces First Quarter 2009 Results 2Health News:West Announces First Quarter 2009 Results 3Health News:West Announces First Quarter 2009 Results 4Health News:West Announces First Quarter 2009 Results 5Health News:West Announces First Quarter 2009 Results 6Health News:West Announces First Quarter 2009 Results 7Health News:West Announces First Quarter 2009 Results 8Health News:West Announces First Quarter 2009 Results 9Health News:West Announces First Quarter 2009 Results 10Health News:West Announces First Quarter 2009 Results 11Health News:West Announces First Quarter 2009 Results 12Health News:West Announces First Quarter 2009 Results 13Health News:West Announces First Quarter 2009 Results 14Health News:West Announces First Quarter 2009 Results 15Health News:West Announces First Quarter 2009 Results 16Health News:West Announces First Quarter 2009 Results 17Health News:West Announces First Quarter 2009 Results 18Health News:Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification 2Health News:Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification 3Health News:Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification 4Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 2Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 3Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 4Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 5Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 6Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 7Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 8Health News:Gentiva Reports First Quarter 2009 Results 2Health News:Gentiva Reports First Quarter 2009 Results 3Health News:Gentiva Reports First Quarter 2009 Results 4Health News:Gentiva Reports First Quarter 2009 Results 5Health News:Gentiva Reports First Quarter 2009 Results 6Health News:Gentiva Reports First Quarter 2009 Results 7Health News:Gentiva Reports First Quarter 2009 Results 8Health News:Gentiva Reports First Quarter 2009 Results 9
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... 2, 2011 Reportlinker.com announces ... report is available in its ... Cardiology Devices: World Market Prospects ... http://www.reportlinker.com/p0663863/Interventional-Cardiology-Devices-World-Market-Prospects-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine Our ...
... 2, 2011 Syndax Pharmaceuticals, Inc ., a ... in a subset of patients from ENCORE 301, a ... entinostat in advanced breast cancer patients, will be presented ... for Cancer Research (AACR) Molecular Targets and Cancer Therapeutics ...
Cached Medicine Technology:Interventional Cardiology Devices: World Market Prospects 2011-2021 2Interventional Cardiology Devices: World Market Prospects 2011-2021 3Interventional Cardiology Devices: World Market Prospects 2011-2021 4Interventional Cardiology Devices: World Market Prospects 2011-2021 5Interventional Cardiology Devices: World Market Prospects 2011-2021 6Interventional Cardiology Devices: World Market Prospects 2011-2021 7Interventional Cardiology Devices: World Market Prospects 2011-2021 8Interventional Cardiology Devices: World Market Prospects 2011-2021 9Interventional Cardiology Devices: World Market Prospects 2011-2021 10Interventional Cardiology Devices: World Market Prospects 2011-2021 11Interventional Cardiology Devices: World Market Prospects 2011-2021 12Interventional Cardiology Devices: World Market Prospects 2011-2021 13Interventional Cardiology Devices: World Market Prospects 2011-2021 14Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011 2Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: